Patient, donor, and transplantation characteristics
| . | ALL, n = 27 n (%) . | AML/MDS, n = 33 n (%) . |
|---|---|---|
| Patient and disease characteristics | ||
| Female | 12 (44%) | 16 (48%) |
| Median age at diagnosis (range), y | 11.8 (0.8-20.1) | 10.2 (0.7-17.7) |
| Median age at transplant (range), y | 13.9 (1.7-23.2) | 11.4 (1.2-18) |
| Disease phase at HSCT | ||
| CR1 | 10 (37%)* | 20 (61%) |
| CR2 | 14 (52%) | 10 (30%) |
| CR3 | 3 (11%) | 0 (0%) |
| MDS | 0 (0%) | 3 (9%) |
| Lymphoblastic leukemia characteristics | ||
| T-ALL | 5 (19%) | † |
| Favorable‡ B-ALL genetics | 2 (7%) | † |
| Intermediate‡ B-ALL genetics | 3 (11%) | † |
| High-risk‡ B-ALL genetics | 9 (33%) | † |
| Myelogenous leukemia characteristics | ||
| Primary AML, reason for transplant | † | 11 (33%) |
| High-risk cytogenetics§ | † | 5 (15%) |
| End induction MRD-positive | † | 4 (12%) |
| Secondary AML | † | 10 (30%) |
| Relapsed (HSCT at CR2) AML | † | 3 (9%) |
| MDS | ||
| Prior immunotherapy and targeted therapy | ||
| Blinatumomab | 10 (37%) | NA |
| Inotuzumab | 6 (22%) | NA |
| CD19-directed CAR T-cell | 7 (26%) | NA |
| Disease burden at transplant start | ||
| MRD negative | 22 (77%) | 26 (87%) |
| MRD positive | 3 (23%) | 4 (13%) |
| Not applicable (MDS) | † | 3 (9%) |
| Transplant characteristics | ||
| HLA compatibility | ||
| MUD | 14 (52%) | 23 (70%) |
| MMUD | 13 (48%) | 10 (30%) |
| Class I mismatch | ||
| A locus | 4 | 5 |
| B locus | ∼ | 4 |
| C locus | 4 | ∼ |
| Class II mismatch | ||
| DR locus | 2 | ∼ |
| DQ locus | 3 | ∼ |
| Class I and II mismatch | ||
| A and DQ | ∼ | 1 |
| DP match status | ||
| Match | 5 (19%) | 5 (15%) |
| Permissive mismatch | 9 (33%) | 10 (30%) |
| Nonpermissive mismatch | 7 (26%) | 10 (30%) |
| Unknown | 6 (22%) | 8 (24%) |
| Donor sex, female | 15 (56%) | 14 (42%) |
| Donor sex mismatch, female donor → male recipient | 6 (22%) | 6 (18%) |
| CMV status (recipient/donor) | ||
| Negative/negative | 6 (22%) | 11 (33%) |
| Negative/positive | 6 (22%) | 4 (12%) |
| Positive/positive | 8 (30%) | 7 (21%) |
| Positive/negative | 7 (26%) | 11 (33%) |
| Conditioning | ||
| TBI based | 27 (100%) | 7 (21%) |
| Busulfan based | 0 (0%) | 26 (79%) |
| ATG containing | 6 (22%) | 15 (45%) |
| Rituximab | 22 (81%) | 27 (82%) |
| Cell dose infused, median (range) | ||
| CD34+ cells × 106/kg | 9.6 (3.2-15.3) | 10.8 (2.9-20) |
| TCRαβ × 105/kg | 0.3 (0.0-4.3) | 0.3 (0.0-4.5) |
| TCRλδ × 106/kg | 7.7 (0.3-48.1) | 6.8 (1.4-51) |
| . | ALL, n = 27 n (%) . | AML/MDS, n = 33 n (%) . |
|---|---|---|
| Patient and disease characteristics | ||
| Female | 12 (44%) | 16 (48%) |
| Median age at diagnosis (range), y | 11.8 (0.8-20.1) | 10.2 (0.7-17.7) |
| Median age at transplant (range), y | 13.9 (1.7-23.2) | 11.4 (1.2-18) |
| Disease phase at HSCT | ||
| CR1 | 10 (37%)* | 20 (61%) |
| CR2 | 14 (52%) | 10 (30%) |
| CR3 | 3 (11%) | 0 (0%) |
| MDS | 0 (0%) | 3 (9%) |
| Lymphoblastic leukemia characteristics | ||
| T-ALL | 5 (19%) | † |
| Favorable‡ B-ALL genetics | 2 (7%) | † |
| Intermediate‡ B-ALL genetics | 3 (11%) | † |
| High-risk‡ B-ALL genetics | 9 (33%) | † |
| Myelogenous leukemia characteristics | ||
| Primary AML, reason for transplant | † | 11 (33%) |
| High-risk cytogenetics§ | † | 5 (15%) |
| End induction MRD-positive | † | 4 (12%) |
| Secondary AML | † | 10 (30%) |
| Relapsed (HSCT at CR2) AML | † | 3 (9%) |
| MDS | ||
| Prior immunotherapy and targeted therapy | ||
| Blinatumomab | 10 (37%) | NA |
| Inotuzumab | 6 (22%) | NA |
| CD19-directed CAR T-cell | 7 (26%) | NA |
| Disease burden at transplant start | ||
| MRD negative | 22 (77%) | 26 (87%) |
| MRD positive | 3 (23%) | 4 (13%) |
| Not applicable (MDS) | † | 3 (9%) |
| Transplant characteristics | ||
| HLA compatibility | ||
| MUD | 14 (52%) | 23 (70%) |
| MMUD | 13 (48%) | 10 (30%) |
| Class I mismatch | ||
| A locus | 4 | 5 |
| B locus | ∼ | 4 |
| C locus | 4 | ∼ |
| Class II mismatch | ||
| DR locus | 2 | ∼ |
| DQ locus | 3 | ∼ |
| Class I and II mismatch | ||
| A and DQ | ∼ | 1 |
| DP match status | ||
| Match | 5 (19%) | 5 (15%) |
| Permissive mismatch | 9 (33%) | 10 (30%) |
| Nonpermissive mismatch | 7 (26%) | 10 (30%) |
| Unknown | 6 (22%) | 8 (24%) |
| Donor sex, female | 15 (56%) | 14 (42%) |
| Donor sex mismatch, female donor → male recipient | 6 (22%) | 6 (18%) |
| CMV status (recipient/donor) | ||
| Negative/negative | 6 (22%) | 11 (33%) |
| Negative/positive | 6 (22%) | 4 (12%) |
| Positive/positive | 8 (30%) | 7 (21%) |
| Positive/negative | 7 (26%) | 11 (33%) |
| Conditioning | ||
| TBI based | 27 (100%) | 7 (21%) |
| Busulfan based | 0 (0%) | 26 (79%) |
| ATG containing | 6 (22%) | 15 (45%) |
| Rituximab | 22 (81%) | 27 (82%) |
| Cell dose infused, median (range) | ||
| CD34+ cells × 106/kg | 9.6 (3.2-15.3) | 10.8 (2.9-20) |
| TCRαβ × 105/kg | 0.3 (0.0-4.3) | 0.3 (0.0-4.5) |
| TCRλδ × 106/kg | 7.7 (0.3-48.1) | 6.8 (1.4-51) |
, Analysis not done.
Transplant in CR1 for end of induction failure or refractory disease.
Not applicable.
Favorable risk genetics38 : hyperdiploidy or ETV6/RUNX1 fusion; intermediate: iAMP21, IKZF1 deletion, or TCF3/PBX1; high risk: MLL(KMT2A) rearrangements, Philadelphia-chromosome (Ph+), Ph-like, hypodiploidy, and TCF3/HLF fusion.
High-risk genetics defined as: −7, −5/5q-, FLT3 high ITD-AR.